INTRODUCTION
Currently available therapies for multiple myeloma is effective in high dose,
but is associated with severe toxicity. In addition, all patients eventually
relapse. This has resulted in a market ready for the entry of low toxicity
therapies and drugs that will increase response rates and maintain remission.
SCOPE OF THE REPORT
- Detailed coverage of patient potential across the seven major markets, as
well as analysis of the main unmet needs.
- Discussion and analysis of the hot topics presented at this year's leading
oncology conferences, including ASH (American Society of Hematology)
- Overview and analysis of the treatment of multiple myeloma, including and
in-depth analysis of the currently used drug regimens.
- Comprehensive analysis of key late-stage products, with Datamonitor
forecasts of drug revenues to 2010.
REPORT HIGHLIGHT
No new drugs have been approved for the treatment of multiple myeloma in two
decades, leaving physicians using the non-pharmacological means to improve
efficacy of treatment. Consequently, physicians are eagerly awaiting the new
generation of biotechnology manufacturer's drugs. Celgene's Thalomid, Aventis'
Genasense and Millennium's Velcade will be the first market entrants, but high
volume use still awaits subsequent market entrants.
KEY REASONS TO BUY THIS REPORT
- Understand the factors that affect hematologists' treatment options and
prescribing decisions
- Identify areas of the multiple myeloma market that are currently
under-served by competitors
- Benchmark current developmental drugs against an analysis of the current
gold standard MP and VAD regimens
- Leverage your competitive advantages by accessing assessments of all phase
III pipeline drugs
- Enhance sales forecasting and product positioning using Datamonitor's
scenario based sales and epidemiological forecasts
View Cart
